RaySearch Laboratories AB (FRA:27R) Cyclically Adjusted Revenue per Share: €2.42 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:27R RaySearch Laboratories AB FRA:27R
91 GF Score
Price €15.77
GF Value €16.72
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Cyclically Adjusted Revenue per Share?

RaySearch Laboratories AB FRA:27R +0.32% 91 Cyclically Adjusted Revenue per Share is €2.42 as of Mar. 2026. GuruFocus rates FRA:27R with a GF Score™ of 91/100 and a GF Value™ of €16.72 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

RaySearch Laboratories AB's adjusted revenue per share for the three months ended in Mar. 2026 was €0.786. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.42 for the trailing ten years ended in Mar. 2026.

During the past 12 months, RaySearch Laboratories AB's average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of RaySearch Laboratories AB was 18.70% per year. The lowest was 12.50% per year. And the median was 17.15% per year.

As of today (2026-07-31), RaySearch Laboratories AB's current stock price is €15.77. RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.42. RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is 6.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.05.


RaySearch Laboratories AB  (FRA:27R) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.77/2.42
=6.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Related Terms


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 1.63 1.94 2.09 2.47

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 2.29 2.33 2.47 2.42

FRA:27R vs VEEV, BTSG, HQY: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaySearch Laboratories AB Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's Cyclically Adjusted PS Ratio falls into.


FRA:27R
91GF Score
RaySearch Laboratories AB FRA:27R
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RaySearch Laboratories AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.786/133.5600*133.5600
=0.786

Current CPI (Mar. 2026) = 133.5600.

RaySearch Laboratories AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.371 101.019 0.491
201609 0.382 101.138 0.504
201612 0.576 102.022 0.754
201703 0.390 102.022 0.511
201706 0.427 102.752 0.555
201709 0.341 103.279 0.441
201712 0.602 103.793 0.775
201803 0.334 103.962 0.429
201806 0.400 104.875 0.509
201809 0.421 105.679 0.532
201812 0.623 105.912 0.786
201903 0.480 105.886 0.605
201906 0.520 106.742 0.651
201909 0.394 107.214 0.491
201912 0.653 107.766 0.809
202003 0.560 106.563 0.702
202006 0.456 107.498 0.567
202009 0.333 107.635 0.413
202012 0.458 108.296 0.565
202103 0.465 108.360 0.573
202106 0.446 108.928 0.547
202109 0.391 110.338 0.473
202112 0.536 112.486 0.636
202203 0.573 114.825 0.666
202206 0.441 118.384 0.498
202209 0.569 122.296 0.621
202212 0.701 126.365 0.741
202303 0.599 127.042 0.630
202306 0.602 129.407 0.621
202309 0.624 130.224 0.640
202312 0.781 131.912 0.791
202403 0.663 132.205 0.670
202406 0.823 132.716 0.828
202409 0.754 132.304 0.761
202412 0.817 132.987 0.821
202503 0.883 132.825 0.888
202506 0.810 133.699 0.809
202509 0.881 133.480 0.882
202512 1.006 133.390 1.007
202603 0.786 133.560 0.786

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.42 mean?
RaySearch Laboratories AB (FRA:27R) has a Cyclically Adjusted Revenue per Share of €2.42 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share too high?
RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is €2.42. Overall, RaySearch Laboratories AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share of €2.42 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is €2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (FRA:27R) is currently considered Fairly Valued. The stock's GF Value™ is €16.72, compared to a current price of €15.77 — trading 5.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.42. RaySearch Laboratories AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For RaySearch Laboratories AB (FRA:27R), the current Cyclically Adjusted Revenue per Share is €2.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (FRA:27R) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued. The current stock price of €15.77 is trading 5.7% below its estimated GF Value™ of €16.72. GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.

Key valuation signals for FRA:27R:

  • Cyclically Adjusted Revenue per Share: €2.42
  • GF Value™: €16.72 vs. price of €15.77 (5.7% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the FRA:27R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
91GF Score

Get the complete analysis for FRA:27R

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.77
Price
€16.72
GF Value